Apellis Pharmaceuticals, Inc.
APLS
Xếp hạng trong cổ phiếu
#3335
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Giá cổ phiếu
$41.03
Đồng bộ lần cuối: 2026-05-15
Vốn hóa thị trường
$5.25B
Thay đổi (1 ngày)
0.00%
Thay đổi (1 năm)
44.93%
Quốc gia
US
Giao dịch Apellis Pharmaceuticals, Inc. (APLS)
Danh mục
Healthcare
Doanh thu của Apellis Pharmaceuticals, Inc. (APLS)
Doanh thu vào Mar 2026 TTM: $1.11B
Theo các báo cáo tài chính gần đây của Apellis Pharmaceuticals, Inc., doanh thu hiện tại của công ty (TTM) là $1.11B. Trong năm 2023, công ty đạt doanh thu $396.59M tăng so với doanh thu năm 2022, là $75.42M. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của Apellis Pharmaceuticals, Inc. từ 2013 đến 2026
Doanh thu vào cuối mỗi năm
| Năm | Doanh thu | Thay đổi |
|---|---|---|
| 2026 (TTM) | $1.11B | 41.45% |
| 2024 | $781.37M | 97.02% |
| 2023 | $396.59M | 425.83% |
| 2022 | $75.42M | 13.31% |
| 2021 | $66.56M | -73.44% |
| 2020 | $250.65M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
Doanh thu của các công ty hoặc đối thủ tương tự
| Công ty | Doanh thu | Chênh lệch doanh thu | Quốc gia |
|---|---|---|---|
| $12.62B | 1,042.18% |
US
|
|
| $2.23B | 101.58% |
US
|
|
| $15.74B | 1,324.47% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 444.77% |
NL
|
